Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is being evaluated clinically for cancer therapy, selectively induces apoptosis in tumor cell lines without causing toxicity to normal cells. However, its therapeutic potential is limited by occurring resistance in a majority of lung carcinoma, breast and prostate cells. Various chemotherapeutic drugs have been found to enhance TRAIL-induced apoptosis. The objective of this study was to examine whether non-small cell lung cancer (NSCLC) cell line A-549, one of the most drug-resistant tumor cells in human, can be sensitized by doxorubicin (DOX) to TRAIL-mediated apoptosis. We show that DOX and recombinant human TRAIL (TRAIL) have a synergistic cytotoxic effect against A-549 cells in vitro. However, no obvious antitumor effects were observed in A-549 tumor bearing nude mice treated by TRAIL alone, DOX alone or both agents, suggesting that further works should be carried to improve the efficacy of combined treatment of DOX and TRAIL.
Keywords: Apoptosis, A-549 cell lines, Combined treatment, Doxorubicin, Non-Small Cell Lung Cancer, TRAIL, DU-145 cell lines, DOX, NSCLC, therapeutic plateau, angiogenesis, necrosis, tumor, caspases
Letters in Drug Design & Discovery
Title: Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Volume: 8 Issue: 9
Author(s): Li Fan, Liangran Guo, Jinfeng Ren, Yulong Ren, Zhiqing Pang and Xinguo Jiang
Affiliation:
Keywords: Apoptosis, A-549 cell lines, Combined treatment, Doxorubicin, Non-Small Cell Lung Cancer, TRAIL, DU-145 cell lines, DOX, NSCLC, therapeutic plateau, angiogenesis, necrosis, tumor, caspases
Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is being evaluated clinically for cancer therapy, selectively induces apoptosis in tumor cell lines without causing toxicity to normal cells. However, its therapeutic potential is limited by occurring resistance in a majority of lung carcinoma, breast and prostate cells. Various chemotherapeutic drugs have been found to enhance TRAIL-induced apoptosis. The objective of this study was to examine whether non-small cell lung cancer (NSCLC) cell line A-549, one of the most drug-resistant tumor cells in human, can be sensitized by doxorubicin (DOX) to TRAIL-mediated apoptosis. We show that DOX and recombinant human TRAIL (TRAIL) have a synergistic cytotoxic effect against A-549 cells in vitro. However, no obvious antitumor effects were observed in A-549 tumor bearing nude mice treated by TRAIL alone, DOX alone or both agents, suggesting that further works should be carried to improve the efficacy of combined treatment of DOX and TRAIL.
Export Options
About this article
Cite this article as:
Fan Li, Guo Liangran, Ren Jinfeng, Ren Yulong, Pang Zhiqing and Jiang Xinguo, Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo, Letters in Drug Design & Discovery 2011; 8 (9) . https://dx.doi.org/10.2174/157018011797200867
DOI https://dx.doi.org/10.2174/157018011797200867 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis
Current Pharmacogenomics and Personalized Medicine Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Structural Insights into the Molecular Design of ROS1 Inhibitor for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
Current Computer-Aided Drug Design Purification and Characterization of a Novel Lectin with Antiphytovirus Activities from the wild Mushroom Paxillus involutus
Protein & Peptide Letters The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients
Current Cancer Drug Targets Current HPLC Methods for Assay of Nano Drug Delivery Systems
Current Topics in Medicinal Chemistry The Gatekeeping Function in Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine MicroRNAs as Therapeutic Targets for Anticancer Drugs in Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Efficient Purification of rhG-CSF and its PEGylated Forms and Evaluation for In Vitro Activities
Protein & Peptide Letters Recent Advances in PET Imaging for Skeletal Surgery Applications
Recent Patents on Medical Imaging Metabolic Targets of Cardiac HormonesTherapeutic Anti-Cancer Effects
Current Pharmaceutical Design Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry Steroidal Cardiac Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors Exhibit Strong Anti-Cancer Potential <i>in vitro</i> and in Prostate and Lung Cancer Xenografts <i>in vivo</i>
Anti-Cancer Agents in Medicinal Chemistry Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors
Current Pediatric Reviews Poly(lactic acid)-poly(ethylene oxide) Block Copolymers: New Directions in Self-Assembly and Biomedical Applications
Current Medicinal Chemistry A Comprehensive Review on Pharmacognostical Investigation and Pharmacology of Typhonium trilobatum
The Natural Products Journal